Prostatakarzinom

[1] Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (AWMF). S3-Leitlinie. Prostatakarzinom (12.05.2021). AWMF-Register-Nr. 043–022OL.

[2] Bubendorf L, Schöpfer A, Wagner U et al. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol 2000; 31(5): 578–583

[3] Correas JM, Halpern EJ, Barr RG et al. Advanced ultrasound in the diagnosis of prostate cancer. World J Urol 2021; 39(3): 661–676. DOI: 10.1007/s00345–020–03193–0

[4] Giri VN, Hegarty SE, Hyatt C et al. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. Prostate 2019; 79(4): 333–339. DOI: 10.1002/pros.23739

[5] Haffner MC, Zwart W, Roudier MP et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol 2021; 18(2): 79–92. DOI: 10.1038/s41585–020–00400-w

[6] Hansen NL, Barrett T, Lloyd T et al. Optimising the number of cores for magnetic resonance imaging-guided targeted and systematic transperineal prostate biopsy. BJU Int 2020; 125(2): 260–269. DOI: 10.1111/bju.14865

[7] Huang Y, Li ZZ, Huang YL et al. Value of free/total prostate-specific antigen (f/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10 ng/mL: A meta-analysis. Medicine (Baltimore) 2018; 97(13): e0249. DOI: 10.1097/MD.0000000000010249

[8] Lee JKT, Sagel SS, Stanley RI. Computed Body Tomography with MRI Correlation. 2nd ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 1998

[9] Mottet N, Cornford P, Bergh RCN van den et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Arnhem, The Netherlands: European Association of Urology; 2022.

[10] National Comprehensive Cancer Network. NCCN Guidelines. Prostate cancer early detection. 2022.

[11] Nordström T, Vickers A, Assel M et al. Comparison between the four-kallikrein panel and Prostate Health Index for predicting prostate cancer. Eur Urol 2015; 68(1): 139–146. DOI: 10.1016/j.eururo.2014.08.010

[12] Robert Koch-Institut. Zentrum für Krebsregisterdaten. Prostatakrebs (Prostatakarzinom). Stand: 30.09.2022.

[13] Rooij M de, Israël B, Tummers M et al. ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists‘ training. Eur Radiol 2020; 30(10): 5404–5416. DOI: 10.1007/s00330–020–06929-z

[14] Shaish H, Feltus W, Steinman J et al. Impact of a structured reporting template on adherence to prostate imaging reporting and data system version 2 and on the diagnostic performance of prostate MRI for clinically significant prostate cancer. J Am Coll Radiol 2018; 15(5): 749–754. DOI: 10.1016/j.jacr.2018.01.034

[15] Siegel RL, Miller KD, Fuchs HE et al. Cancer statistics, 2022. CA Cancer J Clin 2022; 72(1): 7–33. DOI: 10.3322/caac.21708

[16] Smeenge M, Barentsz J, Cosgrove D et al. Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel. BJU Int 2012; 110(7): 942–948. DOI: 10.1111/j.1464–410X.2012.11072.x

[17] Van Poppel H, Roobol MJ, Chapple CR et al. Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of Urology position and recommendations for 2021. Eur Urol 2021; 80(6): 703–711. DOI: 10.1016/j.eururo.2021.07.024